Review Article

Tranexamic acid in otorhinolaryngology – A contemporary review

Jordan Fuzi a,*, Gideon R. Budiono b, Catherine Meller a, Ian Jacobson a

a Department of Otolaryngology, Head and Neck Surgery, Prince of Wales Hospital, New South Wales, Australia
b Faculty of Medicine, University of New South Wales, Australia

Received 25 March 2020; received in revised form 13 May 2020; accepted 26 May 2020
Available online 16 July 2020

KEYWORDS
Tranexamic acid; Otorhinolaryngology; Surgery; Bleeding

Abstract Tranexamic acid (TXA) is an anti-fibrinolytic agent which has been proven beneficial in multiple surgical specialties where significant bleeding can occur. Whilst it has been widely available for over 40 years its use within Otorhinolaryngology is still limited. Operations in Otorhinolaryngology are particularly varied with some such as tonsillectomy having the potential for significant life threatening bleeding. Other operations are performed within small confined surgical fields and even small amounts of bleeding can significantly detriment surgical field and increase technical difficulty and operative time. This review evaluated the current literature on the benefits of tranexamic acid within the field of Otorhinolaryngology and Head and Neck Surgery. Overall TXA was demonstrated to be a safe drug with no major adverse effects including thromboembolic events reported in any study. It has been shown to be of particular benefit in rhinology by improving surgical field, reducing operative time and reducing postoperative swelling and ecchymosis. The benefit in tonsillectomy is less clear and further studies are required to evaluate its potential use in the reduction of post tonsillectomy haemorrhage rates.

Copyright © 2020 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author. Department of Otolaryngology, Head and Neck Surgery, Prince of Wales and Sydney Hospitals, Barker St, Randwick, NSW, 2031, Australia.
E-mail address: fuzijordan@gmail.com (J. Fuzi).
Peer review under responsibility of Chinese Medical Association.

https://doi.org/10.1016/j.wjorl.2020.05.010
2095-8811/Copyright © 2020 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Operations in Otorhinolaryngology present varied risks of intraoperative and postoperative bleeding. Some, such as tonsillectomy, bear a risk of substantial postoperative bleeding that is potentially life threatening. The UK National Prospective Tonsillectomy Audit revealed 4.9% of adults (>16 years) will develop a secondary post tonsillectomy haemorrhage (PTH), with 1.4% requiring return to theatre. There is evidence that these rates are even higher with the modern electrocautery and haemostatic techniques.

Tranexamic acid (TXA) is an anti-fibrinolytic agent with proven benefits in multiple surgical specialties where significant bleeding can occur. TXA was shown to reduce maternal death from bleeding in primary post partum haemorrhage without an increase in thromboembolic events. Additionally, TXA administered within three hours of major trauma reduced mortality by 10% in trauma patients with bleeding. Similar results have been demonstrated in orthopaedic trauma surgery, with a large meta-analysis showing a reduction in perioperative blood loss and transfusion requirements without a significant effect on risk of thromboembolic complications. Another meta-analysis of the safety of TXA in major orthopaedic surgery indicated no significant increase in venous thromboembolism associated with TXA. Currently, there is no clear consensus on the benefit of TXA within otorhinolaryngology. This narrative review aims to review the current literature detailing the use of TXA within a number of otorhinolaryngological operations.

Pharmacology of tranexamic acid

Tranexamic acid is a synthetic analogue of the amino acid lysine and promotes anti-fibrinolysis by competitively binding to the lysine-binding sites on both plasminogen and plasmin.6,7 This prevents attachment to fibrin and precludes activation of plasminogen to plasmin and subsequent fibrin degradation by plasmin. TXA can be administered intravenously or orally, has an oral bioavailability of 30%–50% and has a relatively short half-life of 2–3 h.6,8,9 It is mostly (95%) excreted via renal clearance and administration must be carefully considered in patients with poor renal function.8,9 The most common adverse effects of TXA include nausea, vomiting, diarrhoea and abdominal cramping. There is a theoretical possibility of an increased risk of thromboembolic disease, including deep vein thrombosis, pulmonary embolism, cerebral thrombosis and myocardial infarction.9 This is a major source of concern with regards to TXA prescribing and has led to the avoidance of its use. Acknowledging these concerns, a number of randomised control studies in many different fields have confirmed its safety.9

Tonsillectomy

Tonsillectomy, despite advances in technology and modern approaches, remains plagued by the risk of postoperative bleeding. A number of studies have attempted to evaluate the effect of TXA on postoperative bleeding in tonsillectomy (Table 1). Outcomes included total intraoperative blood loss, rates of primary or secondary post tonsillectomy haemorrhage and requirement for further surgery to achieve haemostasis.

In 2012, Chan et al performed a meta-analysis on 2 trials, demonstrating a statistically significant reduction in intraoperative blood loss when TXA was given as a single dose at induction (32.73 ml, 95% CI -42.66, -22.78, P < 0.001). However, two more recent studies did not demonstrate benefit from TXA with regards to intraoperative blood loss. Brum et al14 showed no reduction in intraoperative blood loss from a single 10 mg/kg intravenous (IV) TXA dose on anaesthetic induction (P = 0.18), and Soliman et al15 failed to show a statistically significant change in blood loss between three population groups (A: 15 mg/kg IV TXA administered at anaesthetic induction, B: 15 mg/kg IV TXA administered at anaesthetic induction plus a continued infusion of IV TXA at 5 mg/kg/h, C: no TXA). Most recently in 2016, Santosh et al. performed a 50 participant randomised controlled trial, which did demonstrate a statistically significant reduction in mean blood loss (66.12 ml vs 106.84 ml, P < 0.05) when TXA was given as a single IV dose at induction. The safety of TXA was confirmed throughout these studies. Only 3 patients developing minor side effects (nausea, vomiting, and headaches) and no significant adverse effects were reported after administration of TXA.

Regarding PTH, there is currently no clear consensus on the effect of TXA administration. Chan et al undertook a meta-analysis of 5 studies (n = 1670) investigating the effect of TXA administration on rates of PTH. No significant reduction in PTH rates were demonstrated (RR = 0.51, 95% CI 0.25, 1.07, P = 0.08). Unfortunately, no further subgroup analysis was performed to differentiate primary from secondary haemorrhage. Robb’s study suggested a halving of primary PTH rates (0.4% vs. 1%) with TXA on induction, when retrospectively compared to a large national audit on tonsillectomy complications. Hinder et al22 have been the first group to evaluate the use of topical TXA postoperatively since Falbe-Hansen et al in 1974 demonstrated a small increase in haemorrhage rates post topical application of TXA (RR = 1.30, 95% CI 0.60, 2.83). Participants were prescribed a topical TXA solution to be applied from postoperative day 5–10. No significant reduction in secondary PTH rates was demonstrated (19% (study) vs. 22% (control), and similarly there was no significant change in requirements for further surgery for haemostasis. Koizumi’s large retrospective study demonstrated no benefit from TXA but is limited by its failure to describe and compare dose or duration of TXA administration or account for surgical technique.

Within the current literature, the benefit of TXA for tonsillectomy is still unclear, however the safety of its use has overwhelmingly been demonstrated. PTH is the most significant complication of tonsillectomy. It can result in life threatening blood loss, sometimes requiring further surgery to achieve haemostasis. Given its pharmacodynamics and short half-life, it would be unwise to expect a single dose of TXA on induction to impact secondary PTH. Currently, no study has been undertaken to evaluate the use of routine oral TXA in the post-operative period to...
| Study            | Type of Study | Participants | Surgical technique | TXA Administration | Timing of TXA dose | Control | Primary Outcome                          | Main result                                                                 |
|------------------|---------------|--------------|--------------------|--------------------|--------------------|---------|------------------------------------------|-----------------------------------------------------------------------------|
| Chan, 2017       | Meta-Analysis | —            | —                  | Varied             | Varied             | —       | 1. Blood loss volume                    | 1. Mean blood loss by 32.72 ml (P < 0.001)                                   |
|                  |               |              |                    |                    |                    |         | 2. Postoperative haemorrhage rate       | 2. T: 400, C: 1270 (RR = 0.51, P = 0.08)                                    |
| Brum, 2012       | Randomised controlled trial | T: 47 | C: 48 | Cold Steel Tonsillectomy | 10 mg/kg IV         | Induction, 8 h, 16 h post | IV saline | Intraoperative blood loss (ml) | T: 135.1 ± 71.4, C: 158 ± 88.1 (P = 0.197) |
| Soliman, 2015    | Randomised controlled trial | T1: 75 | T2: 75 | Extracapsular tonsillectomy not specified | T1: 15 mg/kg IV bolus + 5 mg/kg/hr infusion | T1: on anaesthetic induction | No treatment | Intraoperative blood loss (ml) | T1: 46.56 ± 5.92, T2: 47.07 ± 5.96, C: 47.17 ± 5.36 (P = 0.691) |
| Santosh, 2016    | Randomised controlled trial | T: 25 | C: 25 | Dissection and snare | 10 mg/kg IV | 3–4 h prior to surgery | No treatment | Intraoperative blood loss (ml) | T: 66.12 ± 40.95, C: 106.84 ± 64.72 (P < 0.05) |
| Falbe-Hansen, 1974 | Randomised Controlled trial | 1050 (groups not specified) | Not specified | 4% tranexamic acid topical | Postoperative | 5% glucose Topical | Postoperative Haemorrhage (No. of cases) | T: 13 patients, C: 10 patients |
| Robb, 2014       | Retrospective analysis | T: 476 | | Coblation | 10–15 mg/kg IV | Perioperative | N/A | Primary Haemorrhage Rate (No. of patients/2 patients (0.4%) developed bleeding postoperatively | T: 19.1%, C: 22.2% (P = 0.44) |
| Hinder, 2015     | Prospective trial | T: 246 | C: 248 | Cold steel + bipolar haemostasis or Coblation | 0.2% tranexamic acid topical | Postoperative day 5–10 | Retrospective cohort – tonsillectomy patients who had not received TXA | • Postoperative bleeding requiring surgery (T: 19.1%, C: 22.2%) |
| Koizumi, 2019    | Retrospective analysis | T: 50,501 | C: 60,427 | Not specified | Intravenous — Dose unspecified | From day of tonsillectomy (otherwise unspecified) | No treatment | Post-tonsillectomy haemorrhage requiring operative haemostasis | T: 1.45%, C: 1.33% (P = 0.64) |
| George, 2011     | Randomised controlled trial | T: 50 | C: 50 | Not specified | 10 mg/kg IV | Preoperative | IV saline | Intraoperative blood loss (ml) | T: 36.64, C: 66.32 (P < 0.001) |

C: control group, T: trial/intervention group, IV: intravenous, N/A: not applicable, RR: risk ratio.
reduce the risk or severity of post tonsillectomy haemorrhage. Furthermore its role in stabilisation of patients experiencing PTH has yet to be determined. Thus no recommendation can currently be made regarding its use postoperatively in routine tonsillectomy.

Head and neck operations

Head and neck surgery includes a multitude of different operations, some of which can result in significant risk of postoperative bleeding. This is especially problematic when bleeding obscures or compresses a patient’s airway. There is little literature on the use of TXA in head and neck cancer surgery (Table 2). In 2015, Das et al performed a randomised control trial evaluating the effect of a single dose of 20 mg/kg IV TXA at anaesthetic induction on perioperative bleeding in unilateral head and neck cancer surgeries. This demonstrated a significant reduction in intraoperative, postoperative and total blood loss in comparison to a control, as well as a significant reduction in requirements for blood, colloid and crystalloid infusions. A similar study subsequently performed by Kulkarni et al, demonstrated a significant difference in post-operative blood loss (Placebo - 200 [120–250] ml vs. TXA - 250 [50–1050] ml, P = 0.009) but with no significant change in transfusion requirements. This confirms the findings by Chen in 2008, who demonstrated that the use of TXA 10 mg/kg preoperatively with a continuous intraoperative dose resulted in a significant reduction in postoperative blood loss (49.7 ml vs. 88.8 ml) without a difference in postoperative drainage duration. Although all studies confirm that TXA administration conveys a statistically significant reduction in blood loss, the authors note the minor clinical significance of the relatively small volumes of blood loss reported.

Rhinoplasty

Rhinoplasty can result in moderate intraoperative blood loss, post-operative epistaxis and periorbital swelling and ecchymosis. The potential therapeutic benefit of TXA in elective rhinoplasty has only recently been investigated. There exist 2 similar meta-analyses evaluating the findings of five randomised control trials (Table 3). The main outcomes assessed included intraoperative blood loss, post-operative swelling and postoperative periorbital ecchymosis. Both McGuire et al and de Vasconcellos et al demonstrated a statistically significant reduction in intraoperative blood loss with TXA in comparison to a control (−41.6 ml, P = 0.004)). Amongst these studies, of potential clinical relevance was Eftekharian’s demonstration that TXA significantly reduced operative time. Meh dizadeh’s randomised controlled trial (RCT) however demonstrated no benefit in this regard from TXA. Amongst the trials, the dosage and route of administration of TXA varies (Table 3), with all regimes demonstrating statistical significance without differences in rates of adverse effects. No significant thromboembolic events were reported within all trials.

| Study | Type of Study | Participants | Surgical technique | TXA Administration | Timing of TXA dose | Control | Primary Outcome | Main result |
|-------|---------------|--------------|-------------------|-------------------|-------------------|---------|----------------|------------|
| Das, 2015 | Randomized controlled trial | T: 40, C: 40 | Unilateral H&N cancer surgeries (modified radical neck dissection) | 20 mg/kg IV | 15 min before anaesthetic induction | IV saline | 1. Intraoperative blood loss (ml) | T: 52.34 ± 10.2, C: 61.02 ± 13.4, P < 0.0001 |
| Kulkarni, 2016 | Randomized controlled trial | T: 108, C: 111 | Composite resection of mandible + neck + neck dissection, pedicled flaps (single or double) | 10 mg/kg IV | 20 min after anaesthetic induction | IV saline | 2. Red cell concentrate transfusion requirements (units) | T: 7.6 ± 4.2, C: 7.8 ± 4.2, P < 0.0001 |
| Chen, 2008 | Randomized controlled trial | T: 26, C: 29 | Modified radical neck dissection, Hemithyroidectomy, Superficial parotidectomy | 10 mg/kg IV + 1 mg/kg/h IV | Intraoperative + postoperative | IV saline | 3. Preoperative + intraoperative drainage tube placement duration (h) | T: 2.69 ± 0.68, C: 2.76 ± 0.68, P = 0.143 |
| | | | | | | | 4. Drainage amount (ml) | T: 88.9 ± 89.9, C: 88.8 ± 89.9, P = 0.941 |

C: control group, T: trial/intervention group, IV: intravenous.
| Study                          | Type of Study       | Participants | Surgical technique                                                                 | TXA Administration | Timing of TXA dose | Control         | Primary Outcome                                                                                     | Main result                                                                                                                                                                                                 |
|-------------------------------|---------------------|--------------|-------------------------------------------------------------------------------------|---------------------|--------------------|------------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| De Vasconcellos, 2018         | Meta-analysis       | —            | —                                                                                   | Varied              | Varied             | IV saline/placebo| 1. Intraoperative blood loss (ml) 2. Periorbital oedema and ecchymosis | 1. Mean difference of 42.28 ($P < 0.01$) 2. Oedema by WMD 0.76 and ecchymosis by WMD 0.94 1. Reduction of 41.6 ($P = 0.004$) 2. Reduced significantly |
| McGuire, 2019                 | Meta-analysis       | —            | —                                                                                   | Varied              | Varied             | IV saline/placebo| 1. Intraoperative blood loss (ml) 2. Periorbital oedema and ecchymosis | 1. Reduction of 41.6 ($P = 0.004$) 2. Reduced significantly |
| Beikaei, 2015                 | Randomised controlled trial | T: 48 C: 48 | Open rhinoplasty using standard technique                                            | 10 mg/kg IV         | After anaesthetic induction 2 h prior to surgery ± 5 days postoperative | IV saline      | Intraoperative blood loss (ml) 2. Periorbital oedema and ecchymosis | T: 43.3 ± 11.0  C: 60.3 ± 9.5 $P < 0.001$ 1. T: 68 ± 21  C: 133 ± 63 $P < 0.05$ 2. Less patients in higher grades in Group T ($P < 0.05$) |
| Sakallıoğlu, 2015             | Randomised controlled trial | T: 25 C: 25 | Open septorhinoplasty with osteotomies and hump reduction                           | 1 g oral + 1 g oral TDS | 1 h prior to surgery | Placebo         | Intraoperative blood loss (ml) 2. Periorbital oedema and ecchymosis | T: 144.8 ± 60.28  C: 199.6 ± 73.05 $P = 0.005$ |
| Eftekharian, 2016             | Randomised controlled trial | T: 25 C: 25 | Not specified                                                                       | 1 g oral            | 2 h prior to surgery | Placebo         | Intraoperative blood loss (ml) 2. Periorbital oedema and ecchymosis | Group T1 and T2 lower than C ($P < 0.01$) but no difference between T1 and T2 |
| Mehdizadeh, 2018              | Randomised controlled trial | T1: 15 T2: 15 C: 15 | Open rhinoplasty with dorsal hump removal and lateral and medial osteotomies              | T1: 10 mg/kg IV T2: 10 mg/kg IV + 8 mg dexamethasone IV | 1 h prior to surgery and three doses every 8 h postoperatively | Placebo         | Periorbital oedema and ecchymosis |                                                                                                                                                                                                 |

C: control group, T: trial/intervention group, IV: intravenous, WMD: weighted mean difference.
Similarly, both postoperative eyelid oedema and peri-orbital ecchymosis were reduced by TXA within these meta-analyses (Table 3).28,29 Interestingly, both Mehdizadeh and Sakalliooglu demonstrated a reduction in peri-orbital oedema and ecchymosis with TXA to a degree similar to the use of systemic steroids.32,34 The authors suggest the same benefit can be achieved using TXA without exposing the patient to the systemic effects of steroids. Given the efficacy demonstrated, these authors recommend the use of TXA to reduce postoperative peri-orbital oedema and ecchymosis. Whilst a statistically significant reduction in bleeding was demonstrated, these authors question the clinical significance of an overall small volume of blood loss.

Sinus surgery

Endoscopic sinus surgery is one of the more common procedures performed in otorhinolaryngology. Haemostasis is vital in ensuring optimal visualisation within the narrow confines of the sinonasal cavity. Lack of visibility as a result of bleeding has been identified as a key obstacle in performing sinus surgery.35 Kim et al36 have recently performed a meta-analysis on the pre- and perioperative use of systemic TXA in endoscopic sinus surgery (Table 4). Amongst the 7 studies comprising 562 participants, 6 studies utilised a single preoperative 10 mg/kg intravenous bolus of TXA, with one study administering a 15 mg/kg preoperative intravenous bolus followed by a continuous 1 mg/kg/h infusion throughout the operation.37–43 This analysis found that operative time and intraoperative blood loss were both statistically lower in the treatment group. As expected, surgeon satisfaction was also statistically higher in the treatment group.36 Interestingly, there was no difference in the incidence of side effects including thromboembolism, nausea and vomiting, and there was no impact on postoperative coagulation profiles. Unfortunately no subgroup analyses were performed evaluating the two administration methods. A previous meta-analysis performed by Pundir demonstrated similar reductions in intraoperative blood loss and improvements in surgical field (Table 4).44 This review was limited by significant heterogeneity amongst medication administration and participant recruitment. Similar results were demonstrated by Eldaba, who found that a single 25 mg/kg intravenous dose of TXA on anaesthetic induction reduced intraoperative bleeding resulting in an improved surgical field and shorter operative time.45 Haemodynamics including heart rate and mean arterial pressure did not differ between the treatment and control groups.

Ghorbani et al46 performed an RCT comparing the effects of preoperative oral clonidine vs intraoperative TXA on bleeding and surgical field quality. They revealed no significant difference in either domain between the two treatments, but did not compare these treatments to a control.

Kang et al recently performed a review on the use of topical TXA to reduce intraoperative bleeding in sinus surgery.47 Meta-analysis demonstrated an overall statistically significant reduction in intraoperative bleeding with topical TXA and significantly improved surgical fields. Additionally, no change in haemodynamics was demonstrated. No increased adverse effects (nausea, emesis or thrombosis) were associated with TXA. Of the four studies analysed, three studies compared TXA to saline whereas only Jahnshahi et al48 demonstrated superiority of TXA with phenylephrine over phenylephrine alone as a control. These authors showed TXA resulted in improved surgical field for the first 30 min and a reduction in operative bleeding (170.49 ml vs. 100.10 ml, \( p = 0.001 \)) compared to phenylephrine.

Abbasi’s RCT is the only study comparing the efficacy of different dosages of TXA.49 It demonstrated that a single IV dose of 15 mg/kg IV TXA significantly reduced intraoperative blood loss (\( p = 0.003 \)) and operative time (\( p = 0.01 \)) compared to a 5 mg/kg IV dose, without a significant increase in side effects (\( p = 0.55 \)).

As detailed above, TXA has been shown to significantly reduce intraoperative blood loss and improve surgical field during endoscopic sinus surgery. Throughout the current literature this has resulted in improved surgeon satisfaction and reduced operative time. In addition, TXA has been shown to be safe with no increased reporting of adverse effects. As such, these authors would suggest the use of TXA either as a single intravenous dose or topically in sinus surgery.

Epistaxis

Epistaxis is a common presentation within the emergency department often requiring time consuming and costly treatment.50,51 A recent Cochrane review analysed 6 studies52–57 evaluating the use of TXA for patients with epistaxis58 (Table 5). This found moderate quality evidence that tranexamic acid reduces the risk of re-bleeding within the first 10 days. Of the studies comparing TXA to a control, two trials used TXA as a regular oral dose over several days55,56 and one study applied a once off topical dose.52 Subgroup analysis of these two administration modalities favoured a regular oral dosage.58 No studies reported the requirement of further intervention. Three studies compared topical TXA to other haemostatic agents (epinephrine/lidocaine combination or phenylephrine)53,54,57 with meta-analysis demonstrating a significantly higher proportion of participants achieving haemostasis within 10 min with TXA. A subsequent meta-analysis by Gottleib,51 of similar papers,52–54 evaluating topical TXA reported no significant difference in rates of haemostasis within 30 min but did demonstrate a significant increase in number of patients discharged within 2 h. Additionally, participants were less likely to re-bleed within the first 24 h and at 1 week with TXA.51 No increase in adverse effects was associated with TXA use in either review.58

Hereditary haemorrhagic telangiectasia (HHT) is a hereditary disorder involving structural weakness of the vessel wall, with over 90% of patients with HHT suffering from recurrent spontaneous epistaxis.59 A recent meta-analysis of three studies60–62 on the use of TXA for treatment of HHT associated epistaxis revealed no significant benefit on frequency or duration of bleeds, mean haemoglobin levels or quality of life.63
| Study            | Type of Study     | Participants | TXA Administration                                                                 | Timing of TXA dose                                      | Control | Primary Outcome                                                                 | Main result                                                                                     |
|------------------|-------------------|--------------|-------------------------------------------------------------------------------------|--------------------------------------------------------|---------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Kim, 2019        | Meta-analysis     |              | Varied - 5 studies: 10 mg/kg IV, 1 study 15 mg/kg IV, 1 study 15 mg/kg IV + 1 mg/kg/h IV | Varied - 6 studies preoperative, 1 study preoperative + continuous infusion | 6 studies IV saline, 1 study ethamsylate              | 1. Operative time 2. Intraoperative blood loss (ml) 3. Quality of the surgical field 4. Surgeon satisfaction | 1. SMD: −0.6, P = 0.0003 2. SMD: −0.66, P < 0.001 3. SMD: −0.80, P < 0.001 4. SMD: 1.74, P < 0.001 |
| Pundir, 2013     | Meta-analysis     |              | Varied - 10 mg/kg IV, 100 mg topical, 500 mg IV, 1000 mg topical, 15 mg/kg IV + 1 mg/kg/h IV | Varied - preoperative, preoperative + continuous infusion, intraoperative | 4 studies IV saline, 1 study no control              | 1. Intraoperative blood loss (ml) 2. Surgical field quality score 3. Operative time | 1. MD: −104.10, P = 0.01 2. SMD: −0.74, P = 0.005 3. MD: −7.59, P = 0.09 |
| Eldaba, 2013     | Randomised trial  | T: 50        | 25 mg/kg IV After anaesthetic induction IV saline                                    | IV saline                                              | 1. Intraoperative blood loss (ml)                    | T: 102 ± 19                                                                                   |
| Ghorbani, 2018   | Randomised trial  | T: 22        | 15 mg/kg IV After anaesthetic induction 0.2 mg PO clonidine (1–1.5 h preoperatively) + IV saline after induction | Hb reduction (g/L)                                    | 1. T: 100 ± 19<br>2. B: 104.10, C: 96.59 P = 0.345 |                                                                                               |
| Jahanshahi, 2014 | Randomised trial  | T: 30        | Three pledgets soaked with TXA 5% + 0.5% phenylephrine for 10 min in each nasal cavity | Preoperative Three pledgets soaked in 0.5% phenylephrine for 10 min in each nasal cavity | 1. Intraoperative blood loss (ml) 2. Surgical field quality | 1. T: 100.10 ± 52.50, C: 170.49 ± 45.87 (P = 0.001) 2. Group C had more patients in higher grades (0–15 min P = 0.002, 16–30 min P = 0.003, 31–45 min P = 0.163) |
| Kang, 2019       | Meta-analysis     |              | Topical - TXA in various concentrations, TXA 5% + 0.5% phenylephrine                  | Intraoperative Topical saline, topical 0.5% phenylephrine for 10 min in each nasal cavity | 1. Surgical field score 2. Operative time 3. Intra operative blood pressure | 1. SMD: −0.71, P < 0.001 2. SMD: −0.89, P < 0.0001 3. SMD: −0.25, P = 0.2954 |
| Abbasi, 2012     | Randomised trial  | A: 35        | A: TXA 5 mg/kg IV After anaesthetic induction —                                    | 1. Intraoperative blood loss (ml) 2. Surgical field quality 3. Haemodynamics | 1. A: 272.74 ± 25.77<br>B: 242.89 ± 51.77 P < 0.003 | 1. A: 272.74 ± 25.77<br>B: 242.89 ± 51.77 P < 0.003 2. B > A, P < 0.005 3. No significant difference between groups |

C: control group, T: trial/intervention group, IV: intravenous, SMD: standardised mean difference, MD: mean difference, Hb: haemoglobin.
In summary, the available literature suggests that topical administration of TXA in epistaxis may shorten time to haemostasis and facilitate earlier discharge, whilst systemic administration of TXA may reduce rates of representation within the first week. The safety of this drug was demonstrated throughout the literature.

Discussion

Tranexamic acid has recently been demonstrated to be of particular benefit in the reduction of bleeding in a number of surgical specialties. These authors endeavoured to review its use within otorhinolaryngology, a surgical specialty that contains a wide variety of operations. Some can result in devastating bleeding whereas others become extremely technically difficult when bleeding occurs due to the narrow confines of the surgical field. Tonsillectomy is a common ENT procedure that bears a high risk of significant postoperative bleeding which can be life threatening and require further surgery. The majority of trials to date have assessed the effect of TXA on intraoperative blood loss and have demonstrated a statistically significant reduction. However, total intraoperative blood loss in tonsillectomy is low and as such the clinical significance of these reductions is questionable. The authors consider secondary PTH as the single most important outcome in tonsillectomy, and further studies evaluating the effect of regular post-operative TXA on secondary PTH rates are required.

The benefit of TXA within rhinology is clearer. It has been shown to reduce postoperative swelling and ecchymosis in rhinoplasty when compared to a control. Its therapeutic benefits are similar to pulse steroids, however given the many adverse effects of systemic steroids, TXA may be the more favourable treatment. Total intraoperative blood loss within sinus surgery is clinically low and post-operative transfusions are rarely required. However, given the narrow confines in which this operation is performed, bleeding can often impair visualisation and significantly increase the difficulty and duration of the operation.35 Both intravenous and topical TXA have been shown to reduce operative time, intraoperative blood loss and surgeon satisfaction in sinus surgery. Jahanshahi et al did demonstrate that TXA + phenylephrine resulted in reduced intraoperative bleeding and improved surgical field in comparison to phenylephrine alone, however did not compare TXA alone to phenylephrine. These authors routinely use topical intranasal lignocaine and adrenaline prior to commencement of endoscopic sinus surgery and a study evaluating the efficacy of both therapies and their potential adverse effects would be highly beneficial.

The evidence for TXA use in epistaxis is more heterogeneous with some studies showing shorter time to haemostasis whilst others failed to demonstrate benefit. However, a recent Cochrane review demonstrated moderate quality evidence that oral TXA reduced rates of rebleeding within 10 days in comparison to a control. As such, regular oral TXA should be considered for high-risk

| Table 5 Characteristics of studies included – epistaxis. |
|---|
| **Study** | **Type of Study** | **TXA Administration** | **Control** |
| Gottlieb, 2019 | Meta-analysis | Topical - TXA gel, TXA 500 mg in 5 ml | Varied (placebo/anterior nasal packing) |
| Joseph, 2018 | Meta-analysis | TXA 10% nasal spray, 1 g TXA 8 hourly oral | Placebo 1. Percentage of re-bleeding within 10 days |
| Hsu, 2019 | Meta-analysis | TXA 10% TXA nasal spray, 1 g TXA 8 hourly oral | Placebo 1. Frequency of epistaxis (per month) |
| T: trial/intervention group, C: control group, RD: risk difference, RR: risk ratio, MD: mean difference. | | | |
patients to reduce rates of rebleeding after initial treatment of epistaxis. A major hesitancy towards the use of TXA is the potential increased risk of thromboembolic events. Throughout this review there is overwhelming evidence that systemic and topical TXA incur minimal to no significant increase in major adverse events, particularly thromboembolism. In some studies there were a few reports of minor side effects including nausea and vomiting however these were short lived.

Conclusion

Within this review TXA has been shown to be a safe drug used for the reduction of bleeding. In otorhinolaryngology specifically, the clinical benefit of its use in rhinology and epistaxis has been demonstrated, however definitive confirmation of clinical benefit remains to be determined in other areas of otorhinolaryngological surgery.

Funding

None.

Declaration of Competing Interest

None.

References

1. Lowe D, Meulen JHPVD. National prospective tonsillectomy audit. Bull R Coll Surgeons Engl. 2003;85:352–353.
2. Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA. Antifibrinolytic drugs for treating primary post-partum haemorrhage. Cochrane Database Syst Rev. 2018;2:CD012964.
3. Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2015:CD004896.
4. Gausden EB, Qudsi R, Boone MD, O’Gara B, Ruzbarsky J, Lorich DG. Tranexamic acid in orthopaedic trauma surgery: a meta-analysis. J Orthop Trauma. 2017;31:513–519.
5. Franchini M, Mengoli C, Marietta M, et al. Safety of intravenous tranexamic acid in patients undergoing major orthopaedic surgery: a meta-analysis of randomised controlled trials. Blood Transfus. 2018;16:36–43.
6. Astedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroenterol Suppl. 1987:137:22–25.
7. Reed MR, Woolley LT. Uses of tranexamic acid. Cont Educ Anaesth Crit Care Pain. 2015;15:32–37.
8. Pabinger I, Fries D, Schöchl H, Streif W, Toller W. Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis. Wien Klin Wochenschr. 2017;129:303–316.
9. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012;72:585–617.
10. Robb PJ. Tranexamic acid - a useful drug in ENT surgery. J Laryngol Otol. 2014;128:574–579.
11. Chan CC, Chan YY, Tanweer F. Systematic review and meta-analysis of the use of tranexamic acid in tonsillectomy. Eur Arch Otorhinolaryngol. 2013;270:735–748.
12. Castelli G, Vogt E. [Result of an antifibrinolytic treatment using tranexamic acid for the reduction of blood-loss during and after tonsillectomy]. Schweiz Med Wochenshr. 1977;107:780–784.
13. George A, Kumar R, Kumar S, Shetty S. A randomized control trial to verify the efficacy of pro-operative intra venous tranexamic Acid in the control of tonsillectomy bleeding. Indian J Otolaryngol Head Neck Surg. 2011;63:20–26.
14. Brum MR, Miura MS, Castro SF, Machado GM, Lima LH, Lubianca Neto JF. Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial. Int J Pediatr Otorhinolaryngol. 2012;76:1401–1405.
15. Soliman R, Alshehri A. Assessment of the effect of tranexamic acid on perioperative bleeding in pediatric patients undergoing tonsillectomy. Egypt J Anaesth. 2015;31:297–301.
16. Santosh UP, Prashanth KB, Abhilash S. A comparative study to verify the efficacy of prooperative intravenous tranexamic acid in control of tonsillectomy bleeding. Otorhinolaryngol Clin. 2016;8:22–25.
17. Ali G, Ascanelli L, Pagluiso G. The prophylactic use of AMCHA in tonsillectomies under general anaesthetic. Clin Assess Minerva Anestesiol. 1976;42:675–677.
18. Castelli G, Vogt E. The hemostatic effect of tranexamic acid during and after tonsillectomy, a controlled trial. Schweiz Med Wschr. 1977;107:780–784.
19. Falbe-Hansen Jr J, Jacobsen B, Lorenzen E. Local application of an antifibrinolytic in tonsillectomy. A double-blind study. J Laryngol Otol. 1974;88:565–568.
20. Vitale W. Results with tranexamic acid in ear, nose and throat surgery. Minerva Otorinolaringologica. 1974;24:130–131.
21. Taborelli G, Bastiani G, Lercari G, Pallestrini EA. Action of tranexamic acid (AMCHA) on posttonsillectomy fibrinolysis. Valsalva. 1974;50:34–50.
22. Robb PJ, Thorning G. Perioperative tranexamic acid in day-case paediatric tonsillectomy. Ann R Coll Surg Engl. 2014;96:127–129.
23. Hinder D, Tschopp K. [Topical application of tranexamic acid to prevent post-tonsillectomy haemorrhage]. Laryngorhinootologie. 2015;94:86–90.
24. Koizumi M, Ishimaru M, Matsu T, Hoshimi K, Yamasoba T, Yasunaga H. Tranexamic acid and post-tonsillectomy hemorrhage: propensity score and instrumental variable analyses. Eur Arch Otorhinolaryngol. 2019;276:249–254.
25. Das A, Chattopadhyay S, Mandal D, et al. Does the preoperative administration of tranexamic acid reduce perioperative blood loss and transfusion requirements after head neck cancer surgery? A randomized, controlled trial. Anesth Essays Res. 2015;9:384–390.
26. Kulikarni AP, Chaukar DA, Patil VP, Metgudmath RB, Hawaldar RW, Divatia JV. Does tranexamic acid reduce blood loss during head and neck cancer surgery. Indian J Anaesth. 2016;60:19–24.
27. Chen CC, Wang CC, Wang CP, Lin TH, Lin WD, Liu SA. Prospective, randomized, controlled trial of tranexamic acid in patients who undergo head and neck procedures. Otolaryngol Head Neck Surg. 2008;138:762–767.
28. de Vasconcellos S, do Nascimento-Junior EM, de Aguiar Mendes MV, Tavares Mendes ML, de Souza Dantas R, Martins-Filho P. Preoperative tranexamic acid for the treatment of bleeding, edema, and ecchymosis in patients undergoing rhinoplasty: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2018;144:816–823.
29. McGuire C, Nurmsoo S, Samargandi OA, Bezuhly M. Role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis in primary elective rhinoplasty: a systematic review and meta-analysis. JAMA Facial Plast Surg. 2019;21:191–198.
30. Belkai A, Ghazipour A, Derakhshande V, Saki N, Nikakhligh S. Evaluating the effect of intravenous tranexamic acid on
intraoperative bleeding during elective rhinoplasty surgery. 

Biomed Pharmacol J. 2015;85E:753–E759.

31. O Sakallıoğlu, Polat C, Soylu E, Düzer S, Orhan I, Akyigit A. The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty. Ann Plast Surg. 2015;74: 392–396.

32. Eftekharian HR, Rajabzadeh Z. The efficacy of preoperative oral tranexamic acid on intraoperative bleeding during rhino-

plasty. J Craniofac Surg. 2016;27:97–100.

33. Ghavimi MA, Taheri Talesh K, Ghoreishizadeh A, Chavoshzadeh MA, Zarandi A. Efficacy of tranexamic acid on side effects of rhinoplasty: a randomized double-blind study. J Craniofac Surg. 2017;45:897–902.

34. Mehdizadeh M, Ghasemi A, Khakzad M, et al. Comparison of the effect of dexamethasone and tranexamic acid, separately or in combination on post-rhinoplasty edema and ecchymosis. Aesthet Plast Surg. 2018;42:246–252.

35. Stellet K, Theodoraki MN, Becker S, Tseekmistranko V, Olzowy B, Ledderose G. Specific stressors in endonasal skull base surgery with and without navigation. Eur Arch Oto-

rhinolaryngol. 2015;272:631–638.

36. Kim DH, Kim S, Kang H, Jin HJ, Hwang SH. Efficacy of tranexamic acid on operative bleeding in endoscopic sinus surgery: a meta-analysis and systematic review. Laryngoscope. 2019;129:800–807.

37. Alimian M, Mohseni M. The effect of intravenous tranexamic acid on blood loss and surgical field quality during endoscopic sinus surgery: a placebo-controlled clinical trial. J Clin Anesth. 2011;23:611–615.

38. Chhapola S, Matta I. Short-term use of tranexamic acid to reduce blood loss in nasal endoscopic surgeries. Clin Rhinol. 2011;4:79–81.

39. Langille MA, Chiarella A, Côté DW, et al. Intravenous tranexamic acid and intraoperative visualization during functional endoscopic sinus surgery: a double-blind randomized controlled trial. Int Forum Allergy Rhinol. 2013;3:315–318.

40. Nuhu S, Goljanian Tabrizi A, Zarkhah L, Rashedi Ashrafi B. Impact of intravenous tranexamic acid on hemorrhage during endoscopic sinus surgery. Iran J Otorhinolaryngol. 2015;27:349–354.

41. El Shal SM, Hasanein R. Effect of intravenous tranexamic acid and epsilon aminocaproic acid on bleeding and surgical field quality during functional endoscopic sinus surgery (FESS). Egypt J Anaesth. 2015;31:1–7.

42. Dongare DH, Saundattikar GY. Comparison of intraoperative bleeding and surgical fields with and without tranexamic acid in Functional endoscopic sinus surgery. Indian J Clin Anesth. 2018;5.

43. Moise A, Agachi L, Dragulin E, Mincu N, Stelea G. Tranexamic acid reduces with 50% the total nasal bleeding of patients that underwent functional endoscopic sinus surgery: 6AP6 – 6. Eur J Anaesthesiol (EJA). 2010;27:115.

44. Pundir V, Pundir J, Georgalas C, Fokkens WJ. Role of tranexamic acid in endoscopic sinus surgery - a systematic review and meta-analysis. Rhinology. 2013;51:291–297.

45. Eldaba AA, Amr YM, Albirmawya OA. Effects of tranexamic acid during endoscopic sinus surgery in children. Saudi J Anaesth. 2013;7:229–233.

46. Ghorbani J, Arastou S, Safavi Naeni A, et al. Comparing the effect of oral chloridine and tranexamic acid on bleeding and surgical field quality during functional endoscopic sinus surgery. Iran J Otorhinolaryngol. 2018;30:255–260.

47. Kang H, Hwang SH. Does topical application of tranexamic acid reduce intraoperative bleeding in sinus surgery during general anesthesia. Braz J Otorhinolaryngol. 2020;86:111–118.

48. Jahanshahi J, Hashemian F, Pazira S, et al. Effect of topical tranexamic acid on bleeding and quality of surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: a triple blind randomized clinical trial. PLoS One. 2014;9, e104477.

49. Abbasi H, Behdad S, Ayatollahi V, Nazemian N, Mirshamsi P. Comparison of two doses of tranexamic acid on bleeding and surgery site quality during sinus endoscopy surgery. Adv Clin Exp Med. 2012;21:773–780.

50. Villwock JA, Jones K. Recent trends in epistaxis management in the United States: 2008-2010. JAMA Otolaryngol Head Neck Surg. 2013;139:1279–1284.

51. Gottlieb M, DeMott JM, Peksa GD. Topical tranexamic acid for the treatment of acute epistaxis: a systematic review and meta-analysis. Ann Pharmacother. 2019;53:652–657.

52. Tibbelin A, Aust R, Bende M, et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL J Otorhinolaryngol Relat Spec. 1995;57:207–209.

53. Zahed R, Moharamzadeh P, Alizadeharasi S, Ghasemi A, Saeedi M. A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a random-

ized controlled trial. Am J Emerg Med. 2013;31:1389–1392.

54. Zahed R, Mousavi Jazayeri MH, Naderi A, Naderpour Z, Saeedi M. Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Acad Emerg Med. 2018;25:261–266.

55. Petruson B. A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngol. 1974;77: 57–61.

56. White A, O’Reilly BF. Oral tranexamic acid in the management of epistaxis. Clin Otolaryngol Allied Sci. 1988;13:11–16.

57. Atabaki P, Samarei R, Aribi MS, Soheili A, Mehryar HR. A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. UNMF. 2017;15:488–496.

58. Joseph J, Martinez-Devesa P, Bellorini J, Burton MJ. Tranexa-

mic acid for patients with nasal haemorrhage (epistaxis). Cochrane Database Syst Rev. 2018;12:CD004328.

59. AAssar OS, Friedman CM, White Jr RI. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngo-

scope. 1991;101:977–980.

60. Gaillard S, Dupuis-Girod S, Boutitle F, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12:1494–1502.

61. Geisthoff UW, Seyfert UT, Kübler M, Bieg B, Plinkert PK, König J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-

controlled cross-over phase IIIB study. Thromb Res. 2014;134: 565–571.

62. Whitehead KJ, Sautter NB, McWilliams JP, et al. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA. 2016;316:943–951.

63. Hsu YP, Hsu CW, Bai CH, Cheng SW, Chen C. Medical treatment for epistaxis in hereditary hemorrhagic telangiectasia: a meta-

analysis. Otolaryngol Head Neck Surg. 2019;160:22–35.

Edited by Jie Gao